Full Text
HTA11 U.S. Commercial Payer and Rare Disease Patient Stakeholder Perceptions of Value of Orphan Drugs

Abstract

Authors

S Narayanan

Back to Volume 25, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×